<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Secondary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> after antimitotic therapy is a rare complication usually observed with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The condition usually progresses to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> with very poor short term prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>CASE REPORT: We report the cases of 2 women who developed <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> 2 and 9 months after treatment associating <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> and fotemustine for visceral <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> of a <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>DISCUSSION: The frequency of these rare complications is probably underestimated because of the rapid unfavourable outcome of metastatic <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We were unable to determine whether <z:chebi fb="0" ids="4305">dacarbazine</z:chebi>, fotemustine or their combination was incriminated in this complication </plain></SENT>
<SENT sid="5" pm="."><plain>Risk could be reduced by carefully determining the cumulative doses of these antimitotics </plain></SENT>
</text></document>